John Newman
Stock Analyst at Canaccord Genuity
(2.03)
# 3,019
Out of 5,127 analysts
89
Total ratings
42.31%
Success rate
-8.16%
Average return
Main Sectors:
Stocks Rated by John Newman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATRA Atara Biotherapeutics | Downgrades: Hold | $25 → $6 | $4.83 | +24.22% | 7 | Jan 13, 2026 | |
| ACET Adicet Bio | Maintains: Buy | $128 → $18 | $7.13 | +152.45% | 7 | Jan 6, 2026 | |
| ACLX Arcellx | Maintains: Buy | $130 | $67.23 | +93.38% | 10 | Dec 8, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $850 → $1,057 | $754.91 | +40.02% | 20 | Dec 4, 2025 | |
| CMPX Compass Therapeutics | Initiates: Buy | $10 | $6.60 | +51.52% | 1 | Dec 3, 2025 | |
| NUVL Nuvalent | Initiates: Buy | $126 | $102.15 | +23.35% | 1 | Nov 12, 2025 | |
| DCTH Delcath Systems | Maintains: Buy | $21 | $10.10 | +107.92% | 2 | Oct 21, 2025 | |
| MCRB Seres Therapeutics | Maintains: Buy | $14 → $22 | $14.11 | +55.92% | 10 | Sep 24, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $14 | $1.69 | +728.40% | 3 | Mar 14, 2025 | |
| BNTX BioNTech SE | Maintains: Buy | $171 | $108.93 | +57.39% | 8 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.55 | +416.13% | 1 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $25 | $5.76 | +334.03% | 2 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $43 | $6.47 | +564.61% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.84 | +493.68% | 2 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $44 | $27.15 | +62.06% | 9 | Feb 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $38 | $14.96 | +154.01% | 2 | Oct 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $27 | $5.48 | +392.70% | 2 | Sep 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Speculative Buy | n/a | $14.56 | - | 1 | Sep 13, 2017 |
Atara Biotherapeutics
Jan 13, 2026
Downgrades: Hold
Price Target: $25 → $6
Current: $4.83
Upside: +24.22%
Adicet Bio
Jan 6, 2026
Maintains: Buy
Price Target: $128 → $18
Current: $7.13
Upside: +152.45%
Arcellx
Dec 8, 2025
Maintains: Buy
Price Target: $130
Current: $67.23
Upside: +93.38%
Regeneron Pharmaceuticals
Dec 4, 2025
Maintains: Buy
Price Target: $850 → $1,057
Current: $754.91
Upside: +40.02%
Compass Therapeutics
Dec 3, 2025
Initiates: Buy
Price Target: $10
Current: $6.60
Upside: +51.52%
Nuvalent
Nov 12, 2025
Initiates: Buy
Price Target: $126
Current: $102.15
Upside: +23.35%
Delcath Systems
Oct 21, 2025
Maintains: Buy
Price Target: $21
Current: $10.10
Upside: +107.92%
Seres Therapeutics
Sep 24, 2025
Maintains: Buy
Price Target: $14 → $22
Current: $14.11
Upside: +55.92%
Allogene Therapeutics
Mar 14, 2025
Maintains: Buy
Price Target: $14
Current: $1.69
Upside: +728.40%
BioNTech SE
Mar 11, 2025
Maintains: Buy
Price Target: $171
Current: $108.93
Upside: +57.39%
Mar 5, 2025
Initiates: Buy
Price Target: $8
Current: $1.55
Upside: +416.13%
Feb 26, 2025
Maintains: Buy
Price Target: $20 → $25
Current: $5.76
Upside: +334.03%
Jul 3, 2024
Maintains: Buy
Price Target: $38 → $43
Current: $6.47
Upside: +564.61%
Jun 23, 2023
Reiterates: Buy
Price Target: $5
Current: $0.84
Upside: +493.68%
Feb 16, 2022
Maintains: Buy
Price Target: $52 → $44
Current: $27.15
Upside: +62.06%
Oct 17, 2017
Maintains: Buy
Price Target: $30 → $38
Current: $14.96
Upside: +154.01%
Sep 13, 2017
Maintains: Buy
Price Target: $12 → $27
Current: $5.48
Upside: +392.70%
Sep 13, 2017
Downgrades: Speculative Buy
Price Target: n/a
Current: $14.56
Upside: -